Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Psyence Biomedical ( (PBM) ) has provided an announcement.
Psyence Biomedical Ltd. has entered into an IP Licensing and Mutual Exclusivity Agreement with Optimi Health Corp., a Canadian psychedelics pharmaceutical manufacturer. This agreement grants Psyence exclusive rights to use Optimi’s psilocybin products for research and clinical trials aimed at treating anxiety, depression, and related conditions within palliative care. The agreement includes provisions for Psyence to manufacture the products under specific circumstances, potentially enhancing its market positioning in the growing field of psychedelic-based therapies.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a biotech company focused on utilizing natural psilocybin for treating psychological trauma, addiction, and related diagnosable disorders. The company is particularly interested in the field of palliative care, where it aims to conduct pre-clinical and clinical studies involving human subjects to explore the safety and effects of psilocybin. Psyence intends to commercialize its findings if trials prove successful.
YTD Price Performance: -99.78%
Average Trading Volume: 768,940
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.29M
See more insights into PBM stock on TipRanks’ Stock Analysis page.
Trending Articles
- Apple’s (NASDAQ:AAPL) AI Connections Proving Troublesome
- Ford (NYSE:F) Sets Up New “Chief of Quality”
- Intel (NASDAQ:INTC) Slips as Shareholders Sue Over Foundry
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
